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Abstract-The effects of endothelin-1 (ET-1) administered i.v. or intracerebroventricularly 
(i.c.v.) on arterial pressure (MAP), heart rate and cardiac output were studied in the conscious 
rat. Systemic injection of ET-1 (0.1 to 1 nmol/kg i.v.) increased dose-dependently MAP and 
decreased heart rate. The doses of 0.3 and 1 nmoVkg produced initially transient hypotension 
and tachycardia which were accompanied by a decrease in total peripheral resistance index 
(TPRI). Cardiac outputwas significantly reduced and TPRI increased during the presser 
response to 0.3 and 1 nmol/kg ET-1. ET-1 i.c.v. (30pmol/kg) produced a profound presser and 
vasoconstrictor response which was followed by cardiovascular collapse and death within 20 
min after i.c.v. injection. Low doses (1 to 10pmollkg) of ET-1 i.c.v. had no effect on the 
cardiovascular system. 
The present data are in accordance with the studies demonstrating biphasic blood pressure 
and heart rate responses to i.v. ET-1 in the rat. Profound cardiac depressor and peripheral 
vasoconstrictor responses were found to accompany the presser phase. Our results also 
showed for the firsttime direct central presser and vasoconstrictor effects of ET-1 insinuating 
that endothelin might be a neuropeptide participating in the central cardiovascular control. 
Introduction 
Endothelin is an endothelium-derived 21-residue 
peptide which has powerful vasoconstrictor 
potency on a variety of isolated blood vessels and 
upon intravenous administration in intact animals 
produces dose-dependent pressor and vasocon-
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strictor effects which are preceded by a transient 
hypotensive and vasodilator response (1, 2, 3, 4, 
5). In the rat the initial hypotensive response to 
endothelin was accompanied by carotid and hind-
quarter skeletal muscle vasodilation and reno-
splanchnic vasoconstriction which were followed 
by increases in blood pressure due to strong 
generalized constriction of all vascular beds ( 5). 
However, these experiments were conducted in 
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the anesthetized paralyzed rat, a preparation 
which might not reveal the full scope of hemodyna-
mic responses to endothelin in the conscious state. 
In the conscious rat, i.v. administration of endo-
thelin was recently reported to produce predomin-
antly vasoconstrictor responses in mesenteric and 
hindquarter blood vessels {6). 
The human endothelin was shown to exist in 
three isoforms; ET-1 identical to the classical 
endothelin isolated originally from porcine and 
human aorta, endothelin-2 identical to the peptide 
originally derived from human endothelial cells 
and endothelin-3 identical to endothelin isolated 
first from rat endothelial cells (2). The three 
isoforms of endothelin exhibited distinct profile of 
cardiovascular activity in anesthetized rats; ET -1 
being most potent vasoconstrictor both in vivo and 
in vitro while endothelin-3 displayed most pro-
faund initial hypotensive response (2). Tissue 
autoradiographic sturlies in rats have demon-
strated that specific high-affinity binding sites for 
ET -1 are distributed not only in vascular and 
cardiac muscle but are abundantly present in the 
central nervous system (7, 8, 9). Therefore, the 
present study was set to examine the effects of 
endothelin on systemic hemodynamic variables as 
weil as on blood pressure and cardiac functions in 
conscious rats after intravenous and intracer· 
ebroventricular (i.c. v.) administration. 
Materials and Methods 
Male Sprague-Dawley rats (300-360 g) were pur-
chased from Taconic Farms (Germantown, N.Y.) 
and housed at 22°C with a 12h/12h Iight/dark 
cycle. After surgical operations the rats were 
housed individually in plastic cages (21 x 27 x 
16cm, W x L x H) with food and water ad libitum. 
Measurement of cardiac output 
The cardiac output was measured by thermo-
dilution technique as previously described in detail 
(10, 11). The principle of this technique is to 
produce a change in heat content of blood at one 
point of the circulation (right atrium) and detect 
the resultant change in temperature at a point 
downstream ( ascending aorta). Although the 
cardiac output values obtained by thermodilution 
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tend to be somewhat higher than those determined 
by electromagnetic ftowmetry (12, 13) or by radio-
active microsphere method (14), the thermo-
dilution method offers many advantages, 
including (a) the possibility to do repeated cardiac 
outpul recordings in a conscious chronically instru-
mented rat and, (b) in contrast to Doppler veloci-
metry (15) or electromagnetic flowmetry (12), 
thermodilution does not require the extensive 
open ehest surgery with high mortality and pro-
longed postoperative recovery. 
Each rat to undergo cardiac output measure-
ments was anesthetized with an intramuscular 
injection of ketamine (130mglkg) and aceproma-
zine (1.3mglkg) and a PE-50 catheter was inserted 
into the left femoral artery. The catheters were 
tunneled under the skin and exited at the nape of 
the neck. An incision was made at the midline of 
the neck from the cricoid to the clavicle, and a 
PE-50 catheter was inserted into the right atrium 
via the external jugular vein. The left common 
carotid artery was exposed and ligated, and a 
thermistor (MX2-780-33 model THMP f 1.5, 
Teflon reusable, Columbus Instruments, OH) was 
advanced through the carotid into the ascending 
aorta. Placement above the aortic valve was con-
firmed in each animal by the shape of the dilution 
curve before the probe was finally sutured to the 
neck muscles and again at the end of experiment. 
The jugular vein catheter and the thermistor Ieads 
were tunneled under the skin to the nape of the 
neck. All catheters and the probe wire were 
secured by a soft spring wire attached to the 
animals's neck using an adhesive collar. Twenty-
four hours after the surgery, the arterial line was 
connected to a pressure transducer (Narco Bio-
Systems model RP 1500i] attached to a strain 
gauge coupler (Narco Bio-Systems type 7032). 
Blood pressure (mean, systolic, diastolic, pulse) 
and heart rate were continuously recorded on a 
Narcotrace 80 computerized physiograph and 
sampled automatically at 30-60 s intervals by a 
Northstar-Hazeltine computer. 
To obtain n1easurements of cardiac output, the 
aortic thermistor was attached to the computer-
ized Cardiomax II (CMX-780-k with microprobe 
option R, Columbus Instruments, OH). The dead 
space of the venous line was first flushed with 50 JJ.l 
of 0.9o/o (wt/vol) NaCl (saline) at room tem-
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perature (22 °C); after a brief stabilization period 
an additional injection of 200 ~1 normal saline 
(22 oc) was rapidly injected into the right atrium 
using a 1 ml syringe, and the blood temperature 
monitared by the aortic therrnistor. The thermo-
dilution curve representing the change in aortic 
temperature was then calculated by the Cardio-
max II. A control period of 15 min included two or 
three cardiac output recordings to test for consis-
tency and placement of the probe. During this time 
period, control values for blood pressure and heart 
rate also were collected. The timer for automatic 
data collection was started and data points for 
blood pressure, heart rate and cardiac output were 
collected immediately before and 1, 2.5, 5, 20, 30 
and 60 min after drug injections. Total peripheral 
resistance (TPR) was calculated by dividing the 
mean arterial pressure by the cardiac output; 
values of cardiac output and TPR were further 
indexed per unit ofweight (kg). Core temperature 
was monitored by the aortic thermoprobe before 
each cardiac output measurement. 
Intracerebroventricular injections 
Rats were anesthetized with ketamine-acepro-
mazine ( see above) and placed on a stereotaxic 
device (David Kopf Instruments, Calif. ). A stain-
less steel guide cannula was inserted through the 
skull and fixed with glue (Eastman 910 Adhesive). 
Coordinates for the injections into the right lateral 
brain ventricle (i.c. v.) were measured from the 
bregma: AP = -O.Smm and L = 1.2mm. On the 
day of the experiment, injections of saline or 
endothelin were made using a premeasured 30-g 
(7 .5 mm) cannula inserted into the ventricular 
space through the guide cannula. The injection 
cannula was then connected via polyethylene 
tubing to a Hatnilton microliter syringe, and a 
volume of 10 ~I of the control or drug solution was 
injected over a period of 30 seconds. The proper 
position of the i.c. v. cannula was determined at the 
end of each experiment by an injection of dye 
(methylene blue) into the cerebral ventricles. 
Statistical analysis of the data 
Data in text and figures are means ± S.E. for the 
given number of rats. Analysis of variance with 
repeated measures (general MANOVA) and 
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ANOVA with Student-Newman-Keul's test (CSS 
Complete Statistical System, StatSoft, 1987) were 
used for statistical analysis of the data. 
Drugs used 
Endothelin-1 (ET -1, porcine endothelin) was pur-
chased from Peptides International. The stock 
solution was dissolved in physiological saline 
(0.9°/o) and stored aliquoted in -20°C. The dil· 
utions were prepared fresh each day. 
Results 
A. Hemodynamic effects of intravenously admin-
istered endothelin 
The effects of increasing doses of ET -1 i. v. on 
hemodynamic variables are summarized in Figure 
1. Intravenous injection of ET-1 at the doses of 
0.1-1 nmol/kg increased dose-dependently mean 
arterial pressure. The two highest doses (0.3 and 
1 nmol/kg) initially decreased blood pressure. The 
pressor responses to ET -1 were accompanied by 
bradycardia and the initial depressor phase by a 
tachycardic response. The maximum increase in 
blood pressure became apparent 2-5 min after the 
in jection of the lower doses of ET -1 and these 
responses subsided within 20 min. After the 
highest dose the maximum pressor effect was 
reached in 10 min and the blood pressure remained 
significantly elevated over the whole observation 
period of 60 min. 
Cardiac index was significantly decreased after 
0.3 and 1 nmol/kg doses of ET-1. The decrease in 
cardiac index after the 1 nmoVkg dose reached its 
maximum 5 min after ET -1 injection and the 
cardiac index remained reduced over 60 min. The 
doses of 0.3 and lnmol/kg of ET-1 initially 
· decreased total peripheral resistance. The de-
crease in total peripheral resistance was followed 
by a sustained vasoconstriction and increase in 
peripheral resistance. 
B. Hemodynamic effects of centrally admin-
istered endothelin 
The hemodynamic responses to i.c.v. administra-
tion of ET-1 at doses of 1, 3, 10 and 30pmol/kg are 
summarized in Figure 2. ET-1 i.c.v. at doses up to 
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Fig. 1 Hemodynamic effects of intravenously administered 
ET-1 in the conscious rat. lncreasing doses of ET-1 (0.03-
lnmoVkg) were injected i.v. at 60 min intervals. Values 
indicate mean ± SEM. The number of animals in each group is 
indicated in parenthesis. Asterisks indicate statistical signifi-
cance from baseline by Student-Newman Keul's test. 
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Fig. l Hemodynamic effects of intracerebroventricularly 
(i.c.v.) administered ET-1 in the conscious rat. Saline (10..-.l) or 
increasing doses of ET-1 (1-30pmoVkg) were injected i.c.v. at 
60 min intervals. Values indicate mean ±SEM. The numberof 
animals in each group is indicated in parenthesis. Asterisks 
indicate statistical significance from saline by Student-Newman 
Keul's test. 
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10pmollkg bad no effect on cardiovascular vari-
ables, whereas the 30pmollkg produced a pro-
faund pressor response and increase in total 
peripheral resistance. The mean arterial pressure 
increased from 123 ± 3 mmHg baseline to 200 ± 
SmmHg within 5 min after the i.c.v. injection. 
Heart rate increased ( + 149 ± 34bpm, p < 0.01 vs. 
saline) 15 min after injection. The pressor and 
tachycardic responses were followed by cardio-
vascular coJJapse and death (in 7 out of 8 animals) 
20 min after the i.c.v. injection of ET-1. The 
cardiovascular response to the 30pmoUkg dose of 
ET-1 i.c.v. was accompanied by barrel rolling 
behaviour within seconds after the i.c. v. injection 
and at the terminal phase grand mal-type con-
vulsions. 
Discussion 
Our results are in accordance with recent reports 
demonstrating pressor responses to intravenous 
endothelin in the rat (1, 2, 3, 4, 5). The present 
study provides a clear mechanism for the increase 
in systemic blood pressure; peripheral vasocon-
striction and elevated TPR. In fact the relatively 
moderate response to ET -1 could be the result of 
the counteracting effect of decreased cardiac out-
put by ET -1. Our results are supported by studies 
showing construction of vascular smooth muscle 
by endothelin in various in vitro preparations ( 1, 
16, 17) and increase regional vascular resistance in 
vivo in the renal>mesenteric>hindquarter blood 
vessels after systemic administration of endothelin 
in intact rats (6, 18). 
Several factors could have contributed to the 
decreased in cardiac index: Heart rate was reduced 
concomitantly with the decreased cardiac index 
and a reftex bradycardia due to the increase in 
systemic pressure could thus confer to the fall in 
cardiac output. An increased afterload due to 
elevated peripheral resistance as well as decreased 
preload due to peripheral vasoconstruction could 
also contribute to the reduced cardiac output. A 
direct negative inotropic effect seems unlikely 
since endothelin was recently shown to increase 
tension in the isolated rat atrial and papillary 
muscle (19). However, reduction in myocardial 
contractility could be secondary to coronary vaso-
constriction (20). 
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At the high doses of ET -1 i. v. the pressor and 
cardiac depressant effects were preceded by hypo-
tensive and vasodilator responses. An initial hypo-
tensive response preceding the pressor phase of 
endothelins has been reported after systemic 
administration of endothelin in a variety of species 
including the rat (1, 2, 3, 4, 5, 6). In the anes-
thetized cat the depressor response was associated 
with tachycardia, an increase in cardiac output and 
reduction of total peripheral resistance (3). In our 
study the cardiac output remained unchanged 
during the hypotension while the total peripheral 
resistance decreased. Species differences may 
explain this discrepancy in response to endothelin 
in the rat vs cat. It might also be possible that due 
to the transient nature of the positive inotropic 
response the increase in cardiac index was not 
detected by the thermodilution technique since 
this method does not allow repetitive measure-
ments within a short (Jess than 60 sec) time frame. 
However, our study clearly indicates that vaso-
dilation leading to decreased peripheral vascular 
resistance underlies the hypotensive response to 
ET-1. 
Our study reports for the first time profound 
hypertensive and tachycardic response and 90°/o 
mortality due to cardiovascular collapse after 
intracerebroventricular application of a picomole 
dose of ET -1 in the conscious rat. The extremely 
high potency of i.c.v. administered ET-1 implies 
that this peptide may be a neuromodulator impor-
tant for the centrat cardiovascular regulation. 
Surprisingly, in our study no clear dose-response 
relationship of the central effects of ET-1 was 
established. This might indicate an extremely 
steep dose-response relationship to ET-1, but 
alternatively an unspecific toxic effect unrelated to 
a specific receptor cannot be excluded. However, 
the presence of specific binding sites for endothelin 
in many brain regions including the hypothalamic 
and brain stem cardiovascular nuclei (7, 8, 9) 
supports the possibility that endothelin might be a 
neurotransmitter. 
In summary the present data demoostrate that 
profound cardiac depressor and peripheral vaso-
constrictor responses underlie the previously des-
cribed changes in blood pressure by ET-1. Our 
results also show that ET -1 is a most potent central 
modulator of the cardiovascular system at doses 
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weil below any known peptide, amine, amino acid 
or other known neurotransmitter or neuromodu-
lator. Therefore we suggest that endothelin might 
be a neuropeptide in the centrat cardiovascular 
control. 
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